Matches in Nanopublications for { ?s ?p "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP870004.RAcK77A4kRe_M7vgo1S1aQWumhpZopU25a9G8_4vItCf8130_assertion description "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP870004.RAcK77A4kRe_M7vgo1S1aQWumhpZopU25a9G8_4vItCf8130_provenance.
- NP250636.RAE0EmdcbEGfY2_3cK0ho9D9Vba_IdVUd7Fm2NBiVgBuA130_assertion description "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP250636.RAE0EmdcbEGfY2_3cK0ho9D9Vba_IdVUd7Fm2NBiVgBuA130_provenance.
- NP933034.RA75ubUcSGL0i52uNfCF1zeYWIPRs_DORnCpVE1JIMG5M130_assertion description "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933034.RA75ubUcSGL0i52uNfCF1zeYWIPRs_DORnCpVE1JIMG5M130_provenance.
- NP298363.RAaS1EYf8lMJL1aDoSDsaK_nKbjIlZ7v3HNkmziDkOfZo130_assertion description "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP298363.RAaS1EYf8lMJL1aDoSDsaK_nKbjIlZ7v3HNkmziDkOfZo130_provenance.
- assertion description "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP936056.RAQB_CLsFIpQUUP61hHbW8HQMiXOX_oIGaJGbhUfWnadI130_assertion description "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP936056.RAQB_CLsFIpQUUP61hHbW8HQMiXOX_oIGaJGbhUfWnadI130_provenance.
- assertion description "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP827151.RAmBlrZROKZVtuNc9obBeR92JmldORNsjOTUeRKPzmI_Q130_assertion description "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827151.RAmBlrZROKZVtuNc9obBeR92JmldORNsjOTUeRKPzmI_Q130_provenance.
- NP936060.RAvdy6xbZNZTkzIohxNQq2KgEcCkAz9Ap3aQVDL44OIN0130_assertion description "[Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP936060.RAvdy6xbZNZTkzIohxNQq2KgEcCkAz9Ap3aQVDL44OIN0130_provenance.